DDX11 and ovarian cancer: Silencing of DDX11 using siRNA reduced cell viability in a series of ovarian cancer cell lines, namely UWB1.289 + BRCA1 (Fig. 1A), OVCAR8, IGROV1, and COV362 (SI Appendix, Fig. S2A) as assessed by crystal violet staining of viable cells upon chronic cisplatin and olaparib drug treatment for 5 to 6 d (Fig. 1A and SI Appendix, Fig. S2A).